1. Home
  2. ENSC vs IDAI Comparison

ENSC vs IDAI Comparison

Compare ENSC & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • IDAI
  • Stock Information
  • Founded
  • ENSC 2003
  • IDAI 2016
  • Country
  • ENSC United States
  • IDAI United States
  • Employees
  • ENSC N/A
  • IDAI N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • IDAI Computer Software: Prepackaged Software
  • Sector
  • ENSC Health Care
  • IDAI Technology
  • Exchange
  • ENSC Nasdaq
  • IDAI Nasdaq
  • Market Cap
  • ENSC 5.5M
  • IDAI 5.5M
  • IPO Year
  • ENSC N/A
  • IDAI N/A
  • Fundamental
  • Price
  • ENSC $2.64
  • IDAI $1.88
  • Analyst Decision
  • ENSC
  • IDAI
  • Analyst Count
  • ENSC 0
  • IDAI 0
  • Target Price
  • ENSC N/A
  • IDAI N/A
  • AVG Volume (30 Days)
  • ENSC 24.9K
  • IDAI 73.9K
  • Earning Date
  • ENSC 05-12-2025
  • IDAI 05-13-2025
  • Dividend Yield
  • ENSC N/A
  • IDAI N/A
  • EPS Growth
  • ENSC N/A
  • IDAI N/A
  • EPS
  • ENSC N/A
  • IDAI N/A
  • Revenue
  • ENSC $5,210,031.00
  • IDAI $3,082,348.00
  • Revenue This Year
  • ENSC N/A
  • IDAI $66.11
  • Revenue Next Year
  • ENSC N/A
  • IDAI N/A
  • P/E Ratio
  • ENSC N/A
  • IDAI N/A
  • Revenue Growth
  • ENSC 133.58
  • IDAI N/A
  • 52 Week Low
  • ENSC $2.12
  • IDAI $0.15
  • 52 Week High
  • ENSC $14.67
  • IDAI $8.96
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 23.45
  • IDAI 38.52
  • Support Level
  • ENSC $3.30
  • IDAI $1.73
  • Resistance Level
  • ENSC $3.58
  • IDAI $2.16
  • Average True Range (ATR)
  • ENSC 0.32
  • IDAI 0.26
  • MACD
  • ENSC -0.05
  • IDAI 0.01
  • Stochastic Oscillator
  • ENSC 22.21
  • IDAI 17.31

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.

Share on Social Networks: